Journal
TRENDS IN CANCER
Volume 6, Issue 7, Pages 580-592Publisher
CELL PRESS
DOI: 10.1016/j.trecan.2020.02.003
Keywords
-
Categories
Funding
- Rutgers Cancer Institute of New Jersey (State of NJ appropriation and National Institutes of Health) [P30CA072720]
- Melanoma Research Foundation Career Development Award
- Breast Cancer Alliance Exceptional Project Grant
- National Institutes of Health [R01CA237586, P50CA121974]
Ask authors/readers for more resources
Epigenetic mechanisms, including DNA methylation, histone post-translational modifications, and chromatin structure regulation, are critical for the interactions between tumor and immune cells. Emerging evidence shows that tumors commonly hijack various epigenetic mechanisms to escape immune restriction. As a result, the pharmaceutical modulation of epigenetic regulators, including 'writers', 'readers', 'erasers', and 'remodelers', is able to normalize the impaired immunosurveillance and/or trigger antitumor immune responses. Thus, epigenetic targeting agents are attractive immunomodulatory drugs and will have major impacts on immuno-oncology. Here, we discuss epigenetic regulators of the cancer-immunity cycle and current advances in developing epigenetic therapies to boost anticancer immune responses, either alone or in combination with current immunotherapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available